| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Arnold E Egger. An explanation of why schizophrenia begins with excitotoxic damage to the hippocampus. Medical hypotheses. vol 81. issue 6. 2014-07-28. PMID:24139723. |
passage through the entorhinal cortex converts a serotonergic signal into a glutamate signal, glutamate being the neurotransmitter of exicitotoxicity. |
2014-07-28 |
2023-08-12 |
mouse |
| J G Rahol. Antidepressants: pharmacological profile and clinical consequences. International journal of psychiatry in clinical practice. vol 5. issue 1. 2014-06-19. PMID:24936991. |
three neurotransmitter systems are implicated in the biological basis of depression: the serotonergic system is thought to be a major component in the development of depression and in the efficacy of antidepressant drugs, while the noradrenergic and dopaminergic systems play lesser roles, but are important in the development of antidepressant side-effects. |
2014-06-19 |
2023-08-13 |
Not clear |
| Marios Politis, Kit Wu, Clare Loane, David J Brooks, Lorenzo Kiferle, Federico E Turkheimer, Peter Bain, Sophie Molloy, Paola Piccin. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. The Journal of clinical investigation. vol 124. issue 3. 2014-05-06. PMID:24531549. |
these findings indicate that striatal serotonergic terminals contribute to lids pathophysiology via aberrant processing of exogenous levodopa and release of dopamine as false neurotransmitter in the denervated striatum of pd patients with lids. |
2014-05-06 |
2023-08-12 |
Not clear |
| Tetsuji Terashima, Kenshu Shirakawa, Masao Maekawa, Naoki Furukawa, Shigeki Yamaguchi, Yuuichi Hor. Differential expression of NMDA receptors in serotonergic and/or GABAergic neurons in the midbrain periaqueductal gray of the mouse. Neuroscience letters. vol 528. issue 1. 2014-05-02. PMID:22975137. |
the pag contains various neurotransmitter phenotypes, which include gabaergic neurons and serotonergic neurons. |
2014-05-02 |
2023-08-12 |
mouse |
| Lars Brichta, Paul Greengard, Marc Flajole. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends in neurosciences. vol 36. issue 9. 2014-04-02. PMID:23876424. |
novel pharmacological strategies must be optimized for pd by: (i) targeting disturbances of the serotonergic, noradrenergic, glutamatergic, gabaergic, and cholinergic systems in addition to the dopaminergic system, and (ii) characterizing alterations in the levels of neurotransmitter receptors and transporters that are associated with the various manifestations of the disease. |
2014-04-02 |
2023-08-12 |
Not clear |
| Yannick Vermeiren, Nathalie Le Bastard, An Van Hemelrijck, Wilhelmus H Drinkenburg, Sebastiaan Engelborghs, Peter P De Dey. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 5. 2014-03-25. PMID:23159046. |
research suggests that altered activities of dopaminergic, serotonergic, (nor)adrenergic, as well as amino acid neurotransmitter systems play a role in the etiopathogenesis of bpsd. |
2014-03-25 |
2023-08-12 |
Not clear |
| Feifan Zhang, Abhishek Bhattacharya, Jessica C Nelson, Namiko Abe, Patricia Gordon, Carla Lloret-Fernandez, Miren Maicas, Nuria Flames, Richard S Mann, Daniel A Colón-Ramos, Oliver Hober. The LIM and POU homeobox genes ttx-3 and unc-86 act as terminal selectors in distinct cholinergic and serotonergic neuron types. Development (Cambridge, England). vol 141. issue 2. 2014-02-25. PMID:24353061. |
using a panel of different terminal differentiation markers, including neurotransmitter synthesizing enzymes, neurotransmitter receptors and neuropeptides, we show that ttx-3 also controls the terminal differentiation program of two additional, distinct neuron types, namely the cholinergic aia interneurons and the serotonergic nsm neurons. |
2014-02-25 |
2023-08-12 |
caenorhabditis_elegans |
| Juliann M Paolicch. The timing of pediatric epilepsy syndromes: what are the developmental triggers? Annals of the New York Academy of Sciences. vol 1304. 2014-02-19. PMID:24279892. |
the neurologic pathways underlying the development of spasms have been identified through pet scans as developmental abnormalities of serotonergic and gabaergic neurotransmitter systems in the brain stem and basal ganglia. |
2014-02-19 |
2023-08-12 |
Not clear |
| F W Foley, N G Larocca, R C Kalb, L S Caruso, Z Shne. Stress, Multiple Sclerosis, and Everyday FunctioningA Review of the Literature with Implications for Intervention. NeuroRehabilitation. vol 3. issue 4. 2014-02-17. PMID:24526157. |
stress affects three biological systems that may be dysregulated in ms: the neuroendocrine system, the sympathetic nervous system, and the serotonergic neurotransmitter system. |
2014-02-17 |
2023-08-12 |
Not clear |
| Angelos Halari. Inflammation, heart disease, and depression. Current psychiatry reports. vol 15. issue 10. 2014-02-11. PMID:23975043. |
diminished vagal tone contributes to a pro-inflammatory status which affects neurotransmitter regulation, specifically serotonergic transmission. |
2014-02-11 |
2023-08-12 |
Not clear |
| Peter R Joyce, John Stephenson, Martin Kennedy, Roger T Mulder, Patrick C McHug. The presence of both serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants increase the risk of borderline personality disorder. Frontiers in genetics. vol 4. 2014-01-16. PMID:24432029. |
dysfunction in the dopaminergic and serotonergic neurotransmitter systems has been demonstrated to be important in the etiology of borderline personality disorder (bpd). |
2014-01-16 |
2023-08-12 |
Not clear |
| Sebastiaan Engelborghs, Kristel Sleegers, Stefan Van der Mussele, Nathalie Le Bastard, Nathalie Brouwers, Christine Van Broeckhoven, Peter Paul De Dey. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 35. issue 1. 2013-12-27. PMID:23334703. |
a prospective, longitudinal study was set up to investigate possible genetic associations of behavioral and psychological signs and symptoms of dementia (bpsd) in alzheimer's disease (ad) with two candidate genes in the serotonergic neurotransmitter pathway: serotonin transporter (slc6a4) and brain-specific tryptophan hydroxylase (tph2). |
2013-12-27 |
2023-08-12 |
Not clear |
| Sebastiaan Engelborghs, Kristel Sleegers, Stefan Van der Mussele, Nathalie Le Bastard, Nathalie Brouwers, Christine Van Broeckhoven, Peter Paul De Dey. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 35. issue 1. 2013-12-27. PMID:23334703. |
the present prospective, longitudinal study showed that mainly frontal lobe symptoms were significantly associated with tph2 and 5-httlpr polymorphisms, pointing toward a role of the serotonergic neurotransmitter system in the pathophysiology of frontal lobe symptoms in ad. |
2013-12-27 |
2023-08-12 |
Not clear |
| Garry G Graham, Michael J Davies, Richard O Day, Anthoulla Mohamudally, Kieran F Scot. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. vol 21. issue 3. 2013-12-18. PMID:23719833. |
as is the case with the nsaids, including the selective cox-2 inhibitors, the analgesic effects of paracetamol are reduced by inhibitors of many endogenous neurotransmitter systems including serotonergic, opioid and cannabinoid systems. |
2013-12-18 |
2023-08-12 |
Not clear |
| Eric Promme. Olanzapine: palliative medicine update. The American journal of hospice & palliative care. vol 30. issue 1. 2013-12-03. PMID:22495793. |
olanzapine blocks multiple neurotransmitter receptors, including dopaminergic (d(1), d(2), d(3), and d(4)), serotonergic (5-hydroxytryptamine 2a [5-ht(2a)], 5-ht(2c), 5-ht(3), and 5-ht(6)), adrenergic (α(1)), histaminic (h(1)), and muscarinic (m(1), m(2), m(3), and m(4)) receptors. |
2013-12-03 |
2023-08-12 |
Not clear |
| S K Bhattacharya, P J Rao, S J Brumleve, S S Parma. Role of putative neurotransmitters in bradykinin-induced catalepsy in the rat. Pharmaceutical research. vol 3. issue 3. 2013-11-26. PMID:24271522. |
further, the recent report from this laboratory that centrally administered bradykinin specifically augments rat brain prostaglandin e2 levels, together with the proposed role of central prostaglandins as modulators of central synaptic transmission, suggests that bradykinin-induced catalepsy is mediated and modulated through pge effects on serotonergic, cholinergic, and dopaminergic neurotransmitter systems. |
2013-11-26 |
2023-08-12 |
rat |
| Clive Ballard, Dag Aarsland, Paul Francis, Anne Corbet. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs & aging. vol 30. issue 8. 2013-10-22. PMID:23681401. |
disruption to cholinergic and serotonergic neurotransmission and synapse activity are highlighted as primary pathological factors in neuropsychiatric symptoms, particularly loss of key neurotransmitter functions, alterations to neuronal receptors in the serotonergic pathway, and regionally specific structural changes that are linked to specific symptoms. |
2013-10-22 |
2023-08-12 |
Not clear |
| Y C Wu, R A Hill, A Gogos, M van den Buus. Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience. vol 239. 2013-10-17. PMID:23085218. |
major neurotransmitter systems including dopaminergic, serotonergic and glutamatergic pathways are modulated and supported by estrogen and bdnf. |
2013-10-17 |
2023-08-12 |
Not clear |
| Laura Hondebrink, Sijie Tan, Elise Hermans, Regina G D M van Kleef, Jan Meulenbelt, Remco H S Westerin. Additive inhibition of human α1β2γ2 GABAA receptors by mixtures of commonly used drugs of abuse. Neurotoxicology. vol 35. 2013-09-10. PMID:23266428. |
since gaba receptors (gaba-r) provide the main inhibitory input on dopaminergic and serotonergic neurons, drug-induced inhibition of gaba-r could contribute to higher neurotransmitter levels and thus toxicity. |
2013-09-10 |
2023-08-12 |
human |
| Lorraine V Kalia, Jonathan M Brotchie, Susan H Fo. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 2. 2013-08-06. PMID:23225267. |
thus, it is now well established that neurotransmitter systems, including glutamatergic, gabaergic, cholinergic, noradrenergic, serotonergic, opioidergic, histaminergic, and adenosinergic systems, are affected in the pathogenesis of pd. |
2013-08-06 |
2023-08-12 |
Not clear |